Skip to main content
Monte Rosa Therapeutics, Inc. logo

Monte Rosa Therapeutics, Inc. — Investor Relations & Filings

Ticker · GLUE ISIN · US61225M1027 US Manufacturing
Open in API
Filings indexed 324 across all filing types
Latest filing 2023-10-26 Capital/Financing Update
Country US United States of America
Listing US GLUE

About Monte Rosa Therapeutics, Inc.

https://www.monterosatx.com/

Monte Rosa Therapeutics is a clinical-stage biotechnology company that develops small molecule precision medicines known as molecular glue degraders (MGDs). The company's proprietary drug discovery platform is engineered to rationally design MGDs that leverage the body's natural protein disposal system to selectively eliminate disease-causing proteins. This approach targets proteins that have been historically considered "undruggable" or are inadequately addressed by existing therapies. By integrating expertise in chemistry, artificial intelligence, structural biology, and proteomics, Monte Rosa is advancing a pipeline of therapeutic candidates primarily for cancer and other serious diseases.

Recent filings

Filing Released Lang Actions
424B5
Capital/Financing Update Classification · 100% confidence The document is a prospectus supplement and accompanying prospectus related to a registered direct offering of pre-funded warrants to purchase common stock. It includes detailed information about the offering terms, risk factors, use of proceeds, and legal matters. The document is filed pursuant to Rule 424(b)(5), which is a prospectus supplement filing under the Securities Act of 1933. This type of document is a capital/financing update as it relates to the company's fundraising activities and securities offering. It is not an annual report, earnings release, or any other type of report but specifically a financing-related disclosure.
2023-10-26 English
8-K
Regulatory Filings Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a Current Report used to announce major events or material definitive agreements by a company. The text describes the entry into a material definitive agreement (a collaboration and license agreement with Roche), interim clinical data announcements, and related press releases and presentations. It does not contain comprehensive financial statements or detailed financial performance data typical of Annual Reports (10-K) or Interim Reports (IR). It also is not a transcript, audit report, or other specialized filing. The document includes multiple press releases and presentations as exhibits, which are typical for an 8-K filing announcing material events and disclosures. Therefore, the filing type is best classified as Regulatory Filings (RNS), which is the fallback category for miscellaneous SEC filings like Form 8-K that do not fit other specific categories.
2023-10-17 English
FORM 3 SUBMISSION
Director's Dealing
2023-08-18 English
Regulatory Filings 2023
Regulatory Filings
2023-08-15 English
10-Q
Interim / Quarterly Report Q2 2023
2023-08-10 English
8-K
Earnings Release Classification · 95% confidence The document is a Form 8-K Current Report filed with the SEC, dated August 10, 2023, announcing the company's financial results for the quarter ended June 30, 2023. It includes a press release as an exhibit with the financial results. The text explicitly states it is a press release announcing quarterly financial results, which corresponds to an Earnings Release. The document length is 3551 characters, which is relatively short but contains the actual announcement of quarterly results, not just a notice of report publication. Therefore, it fits the Earnings Release (ER) category rather than a Regulatory Filing or Report Publication Announcement.
2023-08-10 English

Browse filings by year

7 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.